SEC Rule 14e-3: Tender Offer Insider Trading, No Duty Required

In April 2026, the SEC settled charges against a Jazz Pharmaceuticals employee assigned to the due-diligence team reviewing Jazz’s planned acquisition of Chimerix. He bought $70,000 of Chimerix stock across six brokerage accounts in the two weeks before the deal was announced. He was never an officer, director, or 10% owner of either company, and never filed a Form 3, 4, or 5. The SEC charged him anyway — a Rule 14e-3 tender offer insider trading case, built on the one rule that makes it illegal to trade on merger information even if you owe no fiduciary duty to anyone.

Rule 14e-3 tender offer insider trading cases work differently from the classic insider-trading story. There is no corporate officer breaching a duty to shareholders, no Form 4 trail to follow. The rule was written specifically to reach people who owe no duty to anyone at all — and understanding how it does that also reveals a real blind spot in every Form-4-based tool, this one included.

Rule 14e-3 Tender Offer Insider Trading: What It Actually Prohibits

Rule 14e-3(a) makes it unlawful for any person to buy or sell a company’s stock while possessing material, nonpublic information about a tender offer for it, once the bidder has taken “substantial steps” toward commencing the offer — provided the person got that information, directly or indirectly, from the bidder, the target, or an officer, director, or employee of either. SEC staff guidance confirms this trigger point happens earlier than the offer’s public announcement, which lets the SEC reach trading that happens well before a deal makes headlines.

The critical difference from ordinary insider trading law is what the rule does notrequire. Classic Rule 10b-5 needs proof the trader breached a fiduciary duty — their own duty to shareholders, or one they misappropriated from someone else. Rule 14e-3 skips that step. It applies to “any other person,” regardless of whether they owed a duty to anyone on the other side of the trade. A related provision, Rule 14e-3(d), makes it unlawful to tip that information to someone else when a trading violation is reasonably foreseeable, with a narrow carve-out for good-faith communications to people actually planning or financing the offer.

Why the SEC Needed a Rule With No “Duty” Requirement

Rule 14e-3 exists because of a Supreme Court case the SEC lost. In Chiarella v. United States (1980), a printing-house employee named Vincent Chiarella deduced the identities of takeover targets from draft tender-offer documents crossing his desk — company names blacked out, but decipherable — and traded on it, earning about $30,000 over 14 months. The Supreme Court reversed his conviction: a duty to disclose under Section 10(b) does not arise from mere possession of nonpublic information. Chiarella was “a complete stranger” to the shareholders he traded against, the Court held — he owed them nothing, so he broke no law by trading anyway.

That “no duty, no liability” holding left a visible gap: anyone who could get tender-offer information without becoming an insider of either company could trade on it freely. The SEC adopted Rule 14e-3 roughly six months later to close that gap, dropping the duty requirement for tender-offer trading and extending the prohibition to “any other person” who possesses the information, regardless of how they got it.

How the Supreme Court Upheld It: United States v. O’Hagan

Rule 14e-3’s no-duty design didn’t go unchallenged. In United States v. O’Hagan (1997), the Eighth Circuit had thrown out the rule entirely, ruling the SEC exceeded its authority by writing a trading ban with no breach-of-duty element. The underlying facts: James O’Hagan, a partner at law firm Dorsey & Whitney, traded Pillsbury stock and options using confidential information about Grand Metropolitan’s planned tender offer for Pillsbury — a deal his firm was working on for a different client — and profited more than $4.3 million before the offer became public.

The Supreme Court reversed the Eighth Circuit on both fronts. It upheld Rule 14e-3(a) as a valid exercise of the SEC’s authority under Section 14(e), even without a fiduciary-duty requirement built in. In the same opinion, the Court also validated the “misappropriation theory” under Rule 10b-5 — an outsider like O’Hagan can be liable for securities fraud by misappropriating confidential information in breach of a duty owed to the source of that information, even though he owed no duty at all to the Pillsbury shareholders he traded against. Together, these two holdings are the legal foundation every Rule 14e-3 case since has relied on.

Case Study: The Acquirer’s Own Due-Diligence Analyst

The Chimerix case that opened this article is the most recent example of the pattern. Per the SEC’s April 20, 2026 order, Weizheng Zeng of San Diego was a Jazz Pharmaceuticals employee assigned to the due-diligence team reviewing Jazz’s planned Chimerix acquisition. Between February 19 and March 4, 2025, he bought 19,902.469 Chimerix shares across six brokerage accounts. Jazz announced its cash tender offer on March 5, 2025, and Chimerix stock closed 70.57% higher that day. Zeng’s $69,011 profit was disgorged along with $2,443.25 in prejudgment interest and a matching civil penalty, for violating Sections 10(b) and 14(e) and Rules 10b-5 and 14e-3(a).

Notice what Zeng was not: not an officer of Jazz, not a director of Chimerix, not a 10%-plus owner of either. He had access to MNPI purely through his role on a deal team — exactly the category of trader Rule 14e-3 was written to reach, and classical Rule 10b-5 was not.

Case Study: The Deal Financier Who Couldn’t Wait

Zeng’s case is not an outlier. In a June 2024 settlement, the SEC charged Anders J. Lindgren, Associate Director of Deal Finance and M&A at AstraZeneca, with buying CinCor Pharma stock in late 2022, two days after learning from a colleague that AstraZeneca’s acquisition documents for CinCor would be signed that quarter. CinCor’s stock rose roughly 135% when AstraZeneca announced its tender offer in January 2023. Lindgren’s $682,123 profit was disgorged along with $36,994 in prejudgment interest, a matching civil penalty, and a five-year officer-and-director bar.

Same shape as Zeng: an employee of the acquiring company, working the deal from the finance side rather than a boardroom, trading the target’sstock. “Acquirer employee trades target stock ahead of the tender offer” is a recurring category of Rule 14e-3 case, not a one-off.

Case Study: A Tip That Traveled Three People Before It Was Illegal

The furthest-reaching example shows how far Rule 14e-3’s no-duty design extends down a tip chain. The SEC charged Brian Wong of Secaucus, New Jersey with insider trading ahead of Merck & Co.’s February 2021 tender offer for Pandion Therapeutics, alleging roughly $400,000 in illegal profits under Sections 10(b) and 14(e) and Rules 10b-5 and 14e-3.

Not one person in that chain had a fiduciary relationship to Pandion’s shareholders. Under classical Rule 10b-5 alone, that could have been a real problem for prosecutors. Under Rule 14e-3, it wasn’t — the rule doesn’t care how many hands the information passed through, only that Brian Wong possessed it and traded. A larger 2026 case follows the same logic: the SEC’s complaint against three Shoukat brothers and associates alleges roughly $41 million in profits across several schemes from 2020 to 2024, with the Opiant Pharmaceuticals leg charged under Rule 14e-3 after an investment banker tipped one brother about a pending acquisition.

The Pattern MarketPeel’s Form 4 Feed Will Never Show You

This is the point worth sitting with. MarketPeel, like most retail-facing platforms, builds its insider-trading coverage around Form 4 filings, which exist because Section 16 of the Exchange Act requires officers, directors, and 10%-plus owners to disclose their trades. Zeng, Lindgren, and Brian Wong held none of those positions at the companies whose stock they traded. Legally, they had no Form 4 obligation — which makes their trading structurally invisible to any tool built around Section 16 disclosure, no matter how closely it watches EDGAR. Rule 14e-3 catches this category of trader precisely because it was built for people who fall outside the disclosure system, not despite it.

That gap sits alongside one MarketPeel has covered before: tipper-tippee cases turning on the Dirks personal-benefit test also involve trading that never touches a Section 16 filing. Rule 14e-3 is, if anything, an even wider net, because it drops the personal-benefit and duty analysis altogether for anyone trading ahead of a tender offer specifically.

The 2026 Wrinkle: Faster Tender Offers, Tighter Windows

Rule 14e-3’s trigger point — “substantial steps” toward a tender offer — is about to matter over a shorter calendar. On April 16, 2026, the SEC issued an exemptive order letting qualifying negotiated, all-cash equity tender offers shorten their minimum offering period from 20 business days to 10, provided the target files its Schedule 14D-9 within one business day of commencement and no competing bid exists at announcement. The shortened timeline doesn’t apply to hostile offers, going-private deals, or situations where a rival bid later shows up. WilmerHale’s analysis notes the order gives dealmakers “a powerful incentive to favor tender offers,” potentially saving about a month versus a traditional merger structure.

A faster offer doesn’t change what Rule 14e-3 prohibits, but it compresses the window in which the prohibited trading is likely to happen — and likely to move a stock sharply once discovered. For anyone with early access to a deal team’s calendar, that means less time between “substantial steps” and public announcement, and less time for unusual pre-announcement trading to be flagged before the news breaks and makes it obvious in hindsight.

What Retail Investors Can Actually Do With This

None of this is a signal to trade on — Rule 14e-3 cases only become visible after the SEC has already built one, months or years after the trading happened. But it does change how to read two things visible in real time.

First, a sudden run-up in a takeover target’s stock or options volume before a deal is announced is a fundamentally different animal from a Form 4 cluster-buy signal. A cluster of insider purchases is disclosed, dated, and attributable to named people with a legal obligation to file. Pre-announcement volume with no disclosed buyer behind it is exactly the pattern Rule 14e-3 exists to police — evidence of a potential violation, not a research signal to follow.

Second, once a deal is announced, the Schedule TO and Schedule 14D-9 on EDGAR establish the public timeline — when the offer commenced, when it expires, and whether it qualifies for the shortened 10-business-day track under the 2026 order. That timeline tells you how much runway existed between substantial steps and public disclosure, which is the exact window Rule 14e-3 governs.

Most importantly: “no Form 4 activity around a takeover target” does not mean “no informed trading occurred.” It means any trading came from someone with no Section 16 reporting obligation — the exact population Rule 14e-3 was written to reach, and the exact population no Form-4-based tool, MarketPeel included, will ever surface on its own.